SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck
MRK 100.72+1.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Doc Bones12/12/2006 9:30:45 AM
   of 1580
 
8:30AM Merck

says remains confident in future growth, remains on track to deliver long-term, double-digit compound annual EPS growth from 2005 to 2010 (MRK) 44.01 : Co says that it continues to "execute on its strategy to reclaim its leadership position" in the pharmaceutical industry. Co says building on the five FDA approvals it received in 2006, they anticipate 3 NDA filings in 2007 including MK-0518, a first-in-class HIV integrase inhibitor; Gaboxadol, a novel compound from co's alliance with H. Lundbeck A/S for the treatment of insomnia; and MK-0524A. "Merck's new and in-line pharmaceutical products and vaccines are expected to drive revenue at a compound annual growth rate of 4% to 6% from 2005 to 2010, including 50% of the revenues from the joint ventures from which Merck derives equity income ...We expect bottom-line earnings growth to begin in 2007, excluding restructuring charges and the impact of any potential acquired research expense relating to the anticipated Sirna Therapeutics acquisition." Co remains on track to deliver long-term, double-digit compound annual EPS growth from 2005 to 2010, excludi6g one-time items and restructuring charges. Co reaffirms full-year 2006 EPS guidance of $2.48 to $2.52 (vs consensus of $2.52) excluding the restructuring charges related to site closures and position eliminations. Co also anticipates FY07 EPS of $2.51 to $2.59 (vs consensus $2.58), excluding the restructuring charges related to site closures and position eliminations.

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News